Avadel Pharma (AVDL) Tops Q2 EPS by 14c, Beats on Revenues; Lowers FY17 Revenue Guidance Below Consensus

Go back to Avadel Pharma (AVDL) Tops Q2 EPS by 14c, Beats on Revenues; Lowers FY17 Revenue Guidance Below Consensus
(NASDAQ: AVDL) Delayed: 21.64 --0 (-0%)
Previous Close $21.64    52 Week High
Open $21.64    52 Week Low
Day High $21.64    P/E N/A 
Day Low $21.64    EPS
Volume